Onyx Pharmaceuticals, a drug developer company, will acquire Proteolix, Inc. that could cost as much as $851 million. Proteolix, Inc, is a private biotechnology firm and is working to explore its prospective service program for the cure of many types of cancers. Onyx Pharmaceuticals, Inc announced on Monday, about the deal in which they have signed a decisive agreement to acquire Proteolix, Inc.
Tony Coles, the Chief Executive Officer for Onyx Pharmaceuticals said that the company aims to increase Onyx’s product submissions through licensing agreement or procurements in the oncology field. Company has announced in September that they will focus on a small number of possible partners with cautious and experimental drugs in the central-phase of human tests usually required for U.S. authorization.
Onyx will pay $276 million cash payment for this privately held company from South San Francisco and in this whole procedure company will get Proteolix’s drug aspirant for cancer, named carfilzomib, which is being examined as a cure for numerous non-Hodgkin lymphoma, myeloma, and malignant tumor.
This drug is designed in a way that by using it on regular basis cancer cells can be reduced from the specified area of the body, this drug is entitled to prove less harmful for rest of the body in ratio to other drugs available out there in the market.
Onyx Pharmaceuticals will have to pay another amount of $40 million in the coming year if carfilzomib ranges to a developing breakthrough, and in the case if carfilzomib is approved in Europe and America, the company will pay an additional amount of $535 million along with an amount of $170 million if the Food and Drug Administration agrees to examine a fast analysis of the drug.
Onyx, announced that this precious purchase will help to expand the kidney and liver cancer drug Nexavar, to cure blood cancers patients too.
Comments